

Teva's Response and Contributions to Mitigating the Impact of COVID-19

Business Continuity

~200 million patients continue to have access to our essential medicines

Minimal impact to our **R&D programs** and **product launches**



Positive evolution of **digital capabilities** for field sales force

No job losses related to COVID-19



Sourcing & Production

Our facilities remain open to meet demand for our essential medicines



Adequate inventory of raw materials and finished products across our global network


Safe supply and transport of our medicines and APIs remains largely uninterrupted

Our Employees

The **health and well-being** of our employees is our priority



Number of **people in our facilities limited** to only those who are essential and may not work remotely



Strict guidelines in place to protect and ensure safety of employees including **personal protective equipment, hygiene and social distancing**

Our Communities



Supporting local government and healthcare efforts to curb the pandemic

Millions of tablets of **investigational treatment** are being provided to governments and hospitals

Production of both API and finished doses for **potential treatments** are being secured and scaled